Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Sulfasalazin (ausschl. FMR, N2), ATC M01CX02 f. d. Z. 01.11.26-31.10.28 (zzgl. V.-Option 1x12 Mon)

Section 130a Paragraph 8 SGB V allows health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Sulfasalazin (exclusively FMR in the standard size N2), ATC M01CX02, DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine rebate contracts. A rebate contract under the approval model for the aforementioned active substance comes into force for the first time on 01.11.2026 and ends on 31.10.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.